A recent study with mirabegron 50 mg and 25 mg in Chinese participants with overactive bladder (OAB) has been completed. The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of OAB in Chinese participants. Additionally, the study evaluated the safety of mirabegron for the treatment of OAB, assessed other efficacy variables, and explored different mirabegron starting doses. The study was sponsored by Astellas Pharma China, Inc. and involved 249 participants in China.
---
Source: ClinicalTrials.gov
研究与报告2026年8月23日•1 分钟阅读
Mirabegron Study for OAB Completed
3
1
Astellas Pharma's mirabegron study for overactive bladder in China is completed. The study evaluated efficacy and safety of mirabegron.
由 PharmaCountry 团队整理 · 来源： ClinicalTrials.gov
评分
(0)
(0)
(0)
(0)
(0)
留下您的评分